Relaxin Concentrations in Acute Heart Failure Patients: Kinetics and Clinical Determinants

Solano, J. M. Estevan; Mateo, Juan José Santos; Sánchez-Más, Jesús; Sánchez, Juan Manuel Espinosa; Lopez, M.; Pascual-Figal, Domingo A.

doi:10.1016/j.rec.2016.09.007

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found 17.6% of patients with AHF to have undetectable relaxin‐2 blood concentrations. This incidence lies between the 7% described by Martinez‐Solano et al . and the 25% reported by Pintalhao et al .…”

Section: Discussionsupporting

confidence: 52%

“…We found 17.6% of patients with AHF to have undetectable relaxin-2 blood concentrations. This incidence lies between the 7% described by Martinez-Solano et al 10 and the 25% reported by Pintalhao et al 7 It is likely that differences in the baseline characteristics of the various study populations explain this variation. Remarkably, all of these figures are very much lower than those observed in healthy young people, in whom relaxin-2 concentrations are undetectable in 84% of men and 79% of women.…”

Section: Discussionmentioning

confidence: 60%

See 1 more Smart Citation

The relationship of circulating relaxin‐2 concentrations with short‐term prognosis in patients with acute heart failure: the RELAHF study

Herrero‐Puente

Prieto

García-García

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 60%

The relationship of circulating relaxin‐2 concentrations with short‐term prognosis in patients with acute heart failure: the RELAHF study

Herrero‐Puente

Prieto

García-García

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

“…Even though several works have analysed the concentrations of relaxin-2 in plasma and/or serum in patients with established CVDs, most of them have not studied in depth the possible relationship between relaxin-2 circulating levels and different risk and/or prognostic markers related to the metabolic state and body composition [ 91 , 99 , 118 , 119 , 173 ]. Consequently, providing a strong foundation for this promising field of research could aid in implementing the possible use of relaxin-2 during daily clinical practice as a biomarker, risk predictor, or therapeutic agent in several CVDs.…”

Section: Limitations and Future Perspectivesmentioning

confidence: 99%

Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

Aragón-Herrera

Feijóo‐Bandín

Anido-Varela

et al. 2022

JPM

View full text Add to dashboard Cite

The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular tissues through the specific receptor relaxin family peptide receptor 1 (RXFP1) in the regulation of cardiac metabolism; the induction of vasodilatation; the reversion of fibrosis and hypertrophy; the reduction of inflammation, oxidative stress, and apoptosis; and the stimulation of angiogenesis, with inotropic and chronotropic effects as well. Recent preclinical and clinical outcomes have encouraged the potential use of relaxin-2 (or its recombinant form, known as serelaxin) as a therapeutic strategy during cardiac injury and/or in patients suffering from different cardiovascular disarrangements, especially heart failure. Furthermore, relaxin-2 has been proposed as a promising biomarker of cardiovascular health and disease. In this review, we emphasize the relevance of the endogenous hormone relaxin-2 as a useful diagnostic biomarker in different backgrounds of cardiovascular pathology, such as heart failure, atrial fibrillation, myocardial infarction, ischemic heart disease, aortic valve disease, hypertension, and atherosclerosis, which could be relevant in daily clinical practice and could contribute to comprehending the specific role of relaxin-2 in cardiovascular diseases.

show abstract